pd 98059 has been researched along with pf 956980 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cwynarski, K; Hart, SM; Hoffbrand, AV; Lowdell, MW; Prentice, AG; Samuel, ER; Steele, AJ; Wickremasinghe, RG | 1 |
1 other study(ies) available for pd 98059 and pf 956980
| Article | Year |
|---|---|
The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment.
Topics: Apoptosis; bcl-X Protein; Bone Marrow Cells; Calcium-Calmodulin-Dependent Protein Kinases; Cytochromes c; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation, Leukemic; Humans; Interleukin-4; Janus Kinase 3; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Pyrroles; STAT6 Transcription Factor; Stromal Cells; T-Lymphocytes; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2010 |